Century Therapeutics (IPSC) vs MacroGenics (MGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Century Therapeutics (IPSC) has outperformed MacroGenics (MGNX) over the past year, gaining 129.0% versus a gain of 106.4%. Over five years, MGNX leads with a -82.0% price change compared with -93.4% for IPSC. Century Therapeutics is the larger company by market cap ($231.8 million vs $226.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPSC | MGNX |
|---|---|---|
| Share price | $1.28 | $3.55 |
| Market cap | $231.78M | $226.14M |
| 1-day change | -3.03% | -2.47% |
| YTD return | +28.64% | +120.50% |
| 1-year return | +128.98% | +106.40% |
| 5-year return | -93.37% | -82.02% |
| EPS (TTM) | $-0.93 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.04 | $5.08 |
| 52-week low | $0.435 | $1.29 |
| Distance from 52-week high | -57.89% | -30.12% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +271.09% | +125.35% |
| Average volume | 658.60K | 623.51K |
| Shares outstanding | 181.08M | 63.70M |
| Employees | 78 | 293 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed MGNX by 22.6 percentage points over the past year.
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
IPSC vs MGNX FAQ
Which is bigger, Century Therapeutics or MacroGenics?
Century Therapeutics (IPSC) is larger, with a market capitalization of $231.78M compared with $226.14M for MacroGenics (MGNX).
Which stock has performed better over the past year, IPSC or MGNX?
IPSC returned +128.98% over the past 12 months, compared with +106.40% for MGNX (price return, excluding dividends). Past performance does not predict future results.
Are Century Therapeutics and MacroGenics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Century Therapeutics and Biotechnology: Pharmaceutical Preparations for MacroGenics.